Takeda's Iclusig shows potential to become standard of care in acute lymphoblastic leukemia subtype

In November, Takeda said its blood cancer drug Iclusig topped Novartis’ Gleevec in a phase 3 trial in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).